Literature DB >> 16275976

Questioning the benefits of statins.

Eddie Vos, Colin P Rose.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 16275976      PMCID： PMC1277053          DOI： 10.1503/cmaj.1050120

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  8 in total

1.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.

Authors:  Jacques Genest; Jiri Frohlich; George Fodor; Ruth McPherson
Journal:  CMAJ       Date:  2003-10-28       Impact factor: 8.262

2.  Low and lowered cholesterol and total mortality.

Authors:  Michael H Criqui; Beatrice A Golomb
Journal:  J Am Coll Cardiol       Date:  2004-09-01       Impact factor: 24.094

3.  Prevention of coronary heart disease: statins are even less effective than paper shows.

Authors:  David Taylor; Arnold Jenkins; Philipp Conradi
Journal:  BMJ       Date:  2004-02-14

4.  The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.

Authors:  Douglas G Manuel; Peter Tanuseputro; Cameron A Mustard; Susan E Schultz; Geoffrey M Anderson; Sten Ardal; David A Alter; Andreas Laupacis
Journal:  CMAJ       Date:  2005-04-12       Impact factor: 8.262

5.  Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Authors:  Peter S Sever; Björn Dahlöf; Neil R Poulter; Hans Wedel; Gareth Beevers; Mark Caulfield; Rory Collins; Sverre E Kjeldsen; Arni Kristinsson; Gordon T McInnes; Jesper Mehlsen; Markku Nieminen; Eoin O'Brien; Jan Ostergren
Journal:  Lancet       Date:  2003-04-05       Impact factor: 79.321

6.  Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial.

Authors:  James Shepherd; Gerard J Blauw; Michael B Murphy; Edward L E M Bollen; Brendan M Buckley; Stuart M Cobbe; Ian Ford; Allan Gaw; Michael Hyland; J Wouter Jukema; Adriaan M Kamper; Peter W Macfarlane; A Edo Meinders; John Norrie; Chris J Packard; Ivan J Perry; David J Stott; Brian J Sweeney; Cillian Twomey; Rudi G J Westendorp
Journal:  Lancet       Date:  2002-11-23       Impact factor: 79.321

7.  Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

Authors:  John C LaRosa; Scott M Grundy; David D Waters; Charles Shear; Philip Barter; Jean-Charles Fruchart; Antonio M Gotto; Heiner Greten; John J P Kastelein; James Shepherd; Nanette K Wenger
Journal:  N Engl J Med       Date:  2005-03-08       Impact factor: 91.245

Review 8.  Drug treatment of hyperlipidemia in women.

Authors:  Judith M E Walsh; Michael Pignone
Journal:  JAMA       Date:  2004-05-12       Impact factor: 56.272
  8 in total
  3 in total

1.  Lower is better: implications of the Treating to New Targets (TNT) study for Canadian patients.

Authors:  Eddie Vos
Journal:  Can J Cardiol       Date:  2007-04       Impact factor: 5.223

2.  Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22.

Authors:  Quynh A Truong; Sabina A Murphy; Carolyn H McCabe; Annemarie Armani; Christopher P Cannon
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-04-12

Review 3.  Are there modifiable risk factors which will reduce the excess mortality in schizophrenia?

Authors:  Hiram Joseph Wildgust; Mike Beary
Journal:  J Psychopharmacol       Date:  2010-11       Impact factor: 4.153
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.